On September 12, 2026, the International Society of Urological Pathology (ISUP) will host a “Multidisciplinary Expert Consultation Conference on Precision Biomarker Testing in Bladder and Prostate Cancer“, open to members and non-member clinicians and scientists in pathology, urology, oncology, and related fields. The conference will take place immediately preceding the 38th European Congress of Pathology (ECP 2026) in Stockholm, Sweden, and will be held in person without a hybrid format.

Meeting Objectives:

  1. Review the current landscape and clinical implementation of biomarker testing in bladder and prostate cancer.
  2. Establish standardized, evidence-based recommendations for biomarker testing, interpretation, and reporting.
  3. Define optimal specimen requirements, pre-analytical considerations, and specimen selection strategies for biomarker testing.
  4. Define the role, clinical indications, limitations, and validation requirements of liquid biopsy.
  5. Define the current and future roles of artificial intelligence and digital pathology in biomarker assessment, including workflow integration and quality assurance.
  6. Identify knowledge gaps and research priorities to guide future studies, clinical trials, and guideline development.

 

This Consensus will be Co-Chaired by ISUP members, Dr. Liang Cheng (Providence, RI, USA), and Dr. Geert van Leenders (Rotterdam, Netherlands).

 

Meeting Venue:  Details coming soon

 

Agenda: Details coming soon

 
 

Working Group 1: Biomarker Testing in Bladder Cancer

WG 1 Chairpersons: Michelle R. Downes, Antonio Lopez-Beltran

Working Group 2: Biomarker Testing in Prostate Cancer

WG2 Chairpersons: Gladell P. Paner, Alessia Cimadamore

 
 
 
 
 

General questions: Katrina Collins  katrinacollinsmd@gmail.com and/or Nancy Greenland nancy.greenland@ucsf.edu

Partially sponsored by: